Carigent Therapeutics Inc.
Carigent is a privately held biotechnology firm located in New Haven, CT dedicated to the development of next generation therapeutics and diagnostic agents using a propriety drug delivery platform which is extremely versatile and robust. The platform allows for controlled release of therapeutic agents, tethering of surface ligands, targeting of therapy to a particular physiological site, and the ability to combine multiple agents into one vehicle made primarily from FDA approved materials. The technology is unique since it incorporates a high density of surface ligands into established, well-characterized, safe materials which allow…
§ incredible flexibility in targeting the delivery system for a variety of disease states
§ ability to combine imaging agents with drug, and/or
§ enhancment of in vivo circulation times.
The company was founded in 2007 with a team focused on generating a comprehensive product pipeline in multiple therapeutic areas including cancer treatment, antibody therapeutics, and siRNA delivery. The business strategy centers on the core technology of surface-modified, nanoparticle encapsulation of therapeutic agents where Carigent develops drug products both internally and in collaboration with pharmaceutical and biotechnology industry leaders, using generic, commercially available drugs or proprietary compounds.
5 Science Park, Suite 13
New Haven, CT 06520 USA
203 752 0808
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||